The 2025-2030 World Outlook for Dermatological Drugs

The 2025-2030 World Outlook for Dermatological Drugs

This study covers the world outlook for dermatological drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

In this report we define the sales of dermatological drugs as including all commonly understood products falling within this broad category, such as psoriasis, skin infections, acne, and dermatitis drugs, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include 23andMe, Abbott, AbbVie, Ablynx, Actavis, Advent International, AET Biotech, Alkem Laboratories, Allergan, Almirall, American Academy of Dermatology (AAD), Amgen, Anacor, ARMO Biosciences, Ascend Therapeutics, Astellas, Aurovindo, Avanir Pharmaceuticals, Barr Labs, Bausch Health Companies, Bayer, Betta Pharmaceuticals, Biocon/Mylan, Biofrontera, Biogen, Biovail Laboratories, BioXpress Therapeutics, Boehringer Ingelheim, Brazilian Society of Dermatology, Bristol-Myers Squibb, Cadila Healthcare, Calico, Can-Fite BioPharma, Cassiopea SPA, Celgene, Celltrion, Cempra, Cipher Pharmaceuticals, Cipla, Colorescience, Concert Pharmaceuticals, Cubist Pharmaceuticals, Cutanea Life Sciences, Dermavant Sciences, Dow Pharmaceuticals Science, Dr Reddy’s, Durata Therapeutics, Eisai, Eli Lilly, European Commission (EC), FibroTx, Foamix, Food and Drug Administration (FDA), Fougera, Fujifilm, G&E Herbal Biotechnology, Galapagos, Galderma, GlaxoSmithKline, Glenmark Pharmaceuticals, Heritage, Hill Dermaceuticals, Igenica Biotherapeutics, Impax, Incyte, International Health Partners, Janssen, Jazz Pharmaceuticals, Johnson & Johnson, KNOW Bio, Kyowa Hakko Kirin, L’Oreal, L’Oréal, Laboratorios Almirall, SA, LEO Pharma, Lupin, Maruho, Mayne Pharma, Meda Aktiebolag, Medicis, Medison Pharma, Melinta Pharmaceuticals, Merck, MERZ PHARMACEUTICALS, Mitsubishi Tanabe, MorphoSys, Mylan, NanoBio, National Psoriasis Foundation (NPF), NeoStrata Compnay, Inc., Nestlé, Nestle Skin Health, New Moon B.V., Novan, Novartis, Perriogo, Pfizer, Pharmaceuticals and Medical Devices Agency (PMDA), PharmaPraxis, Photocure, Pierre Fabre, Proteostasis Therapeutics, Provectus Biopharmaceuticals, QLT, Inc., Ranbaxy, Regeneron Pharmaceuticals, Renaissance Acquisition Holdings, LLC., Revance Therapeutics, Rigontec, Roche, Roivant Sciences, Samsung Bioepis, Sandoz, SangStat, Sanofi, Schering-Plough, Shanghai CP Buojian Pharmaceutical, Sidmak Labs, Sol-Gel Technologies, Stiefel Laboratories, Sun Pharma, Takeda, Tanabe, Tanja Todberg, Taro Pharmaceuticals, Teva, The University of Texas MD Anderson Cancer Center, Topica Pharmaceuticals, UCB, Universal Cells, Inc., Valeant, Vical, Viralytics, Warner Chilcott, Watson Pharmaceuticals, Xenon Pharmaceuticals, Ziarco Group, Ltd., and Zydus. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2024).